At a median follow-up of 15.9 months, the median duration of response was not reached.
The “myTcell” app is expected to be released in the United States in 2022.
There was no difference in overall survival between patients with MDS/CMML and those with AML.
Response rates and overall survival were superior in the triplet group.
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
The findings of this study prompted a change in clinical practice.
Outcomes were similar to those seen in the ZUMA-2 trial.
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
The disparity was driven by patients aged 18-29 years.
Researchers presented updated findings from the GLOW trial.
Most outcomes were similar for patients who received gilteritinib plus azacitidine and those who received azacitidine alone.
Most events occurred during treatment cycles 1 and 2.
The median event-free survival was 3 months in both treatment arms.
Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
GO plus cytarabine was no more effective than standard chemotherapy and appeared particularly detrimental for women.
The median duration of response was 14.7 months.